MarketPulse

Phase 2a trial

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Aclaris Therapeutics, Inc.

Aclaris to Present Phase 2a ATI-2138 Data at 2026 AAD Meeting

Aclaris Therapeutics will present previously unreported Phase 2a trial results for ATI-2138, an oral dual ITK/JAK3 inhibitor, at the 2026 AAD Annual Meeting in Denver.
ACRSclinical trial resultsatopic dermatitis
GlobeNewswire Inc.GlobeNewswire Inc.··Na

OKYO Pharma CDO Backs Pipeline With $49K Share Purchase as Phase 2b/3 Trial Looms

OKYO Pharma's Chief Development Officer purchases 30,980 shares at $1.59, signaling confidence in urcosimod as company prepares Phase 2b/3 trial launch in H1 2026.
OKYOclinical-stage biopharmaceuticalneuropathic corneal pain
GlobeNewswire Inc.GlobeNewswire Inc.··Na

OKYO Pharma's Neuropathic Eye Pain Therapy Earns ARVO 2026 Presentation Slot

OKYO Pharma's urcosimod earns ARVO 2026 presentation slot for neuropathic eye pain therapy. Phase 2a data shows pain reduction and quality-of-life improvements; Phase 2b/3 trial planned for 2026.
OKYOclinical trial resultsneuropathic corneal pain
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Starton Advances Subcutaneous Lenalidomide Program With Phase 2a Multiple Myeloma Trial Launch

Starton launches Phase 2a trial for subcutaneous lenalidomide delivery in multiple myeloma, comparing three dose levels against standard oral Revlimid treatment.
BMYCELGrclinical developmentmultiple myeloma